Roschier represented NextPharma in the acquisition of a manufacturing facility and related operations in Tampere from Santen. NextPharma will be taking over the site fully staffed, with 181 employees transferring to NextPharma. The acquisition is expected to be completed in the summer of 2019. NextPharma and Santen are also entering into a strategic partnership under which NextPharma will take over production of Santen products in the Tampere facility.
NextPharma is a leading European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with a current footprint spanning five sites in Germany and one in France. NextPharma supplies products globally, with five of its six sites FDA-approved.
Santen is a company dedicated to the ophthalmic field, which carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products and devices. Santen has long been the market leader in Japan for prescription ophthalmic pharmaceuticals and is now a leader in the sector in the EMEA (Europe, Middle East and Africa) region.